Important Alert for Investors of Semler Scientific: Class Action Launched
Robbins LLP has recently announced the initiation of a class action lawsuit aimed at protecting the interests of stockholders who invested in Semler Scientific, Inc. (SMLR) from March 10, 2021, to April 15, 2025. This legal action specifically supports individuals and entities that purchased or otherwise obtained stocks in the biotechnology company, which focuses on developing innovative technology to manage chronic diseases.
The recent allegations against Semler Scientific involve serious claims of omitted disclosures regarding an ongoing investigation by the United States Department of Justice (DOJ) related to potential violations of the False Claims Act. According to insights from the lawsuit, throughout the class period, the defendants did not adequately inform investors about significant inquiries conducted by the DOJ. These inquiries scrutinized whether Semler was engaging in misleading marketing practices regarding their tests, which exploit photoplethysmography technology, implying that these tests could be reimbursed by Medicare in ways that may contravene established laws and regulations.
On February 28, 2025, Semler disclosed for the first time that they received an initial civil investigative demand (CID) back in July 2017 from the DOJ. This CID prompted investigations focusing on whether the firm's operations constituted violations related to caregiving and reimbursement standards. Despite discussing the potential implications in general terms during presentations, the company is accused of withholding specifics regarding the seriousness and potential penalties of these investigations. As revelations emerged about the numerous subsequent CIDs received by Semler and their unsuccessful settlement discussions with the DOJ on February 11, 2025, investors watched their stock value plummet by 9.38%, resulting in a closing price of $38.89 on March 3, 2025.
Further complicating matters, on April 15, 2025, Semler issued an SEC Form 8-K that highlighted an agreement with the DOJ to settle the investigation for $29.75 million. This disclosure revealed that further financial repercussions could arise in the future, triggering another 9.88% drop in the stock price, finishing at $31.00 on April 16, 2025. This pattern of disclosure has raised eyebrows and alarmed shareholders, as the perceived lack of transparency in managing critical legal matters could signify a breach of investor trust.
For any shareholders of Semler Scientific, now is a crucial moment to become involved in this class action lawsuit. Those wishing to take on the role of lead plaintiff – which would provide the opportunity to represent the interests of the entire class – must file their paperwork by October 28, 2025. It is vital to understand that participating in this lawsuit does not require a financial commitment upfront; representation operates on a contingency basis, meaning shareholders will not incur any legal fees unless a recovery is achieved.
Robbins LLP, a reputable firm recognized for advocating shareholder rights, emphasizes their commitment to helping investors reclaim losses and ensure corporate governance accountability. Their team has been on the forefront of litigations aimed at protecting shareholder interests since the firm’s inception in 2002.
Moreover, all Semler Scientific stakeholders are encouraged to stay informed. One way to do so is by signing up for updates through services provided by Robbins LLP. This ensures investors are alerted to any settlements or new developments regarding misconduct by corporate executives. It’s important that investors are not left uninformed about potential remedies or legal recourse in such precarious financial waters.
If you or anyone you know has endured substantial financial losses due to investments in Semler Scientific, the team at Robbins LLP is available for assistance. Shareholders can reach out to attorney Aaron Dumas, Jr., or call the firm directly at (800) 350-6003 for further clarity and support.
In these challenging times, understanding your rights as a shareholder is vital. Engage, understand, and if necessary, act — your investments deserve the protection and advocacy only a dedicated legal team can provide.
The recent allegations against Semler Scientific involve serious claims of omitted disclosures regarding an ongoing investigation by the United States Department of Justice (DOJ) related to potential violations of the False Claims Act. According to insights from the lawsuit, throughout the class period, the defendants did not adequately inform investors about significant inquiries conducted by the DOJ. These inquiries scrutinized whether Semler was engaging in misleading marketing practices regarding their tests, which exploit photoplethysmography technology, implying that these tests could be reimbursed by Medicare in ways that may contravene established laws and regulations.
On February 28, 2025, Semler disclosed for the first time that they received an initial civil investigative demand (CID) back in July 2017 from the DOJ. This CID prompted investigations focusing on whether the firm's operations constituted violations related to caregiving and reimbursement standards. Despite discussing the potential implications in general terms during presentations, the company is accused of withholding specifics regarding the seriousness and potential penalties of these investigations. As revelations emerged about the numerous subsequent CIDs received by Semler and their unsuccessful settlement discussions with the DOJ on February 11, 2025, investors watched their stock value plummet by 9.38%, resulting in a closing price of $38.89 on March 3, 2025.
Further complicating matters, on April 15, 2025, Semler issued an SEC Form 8-K that highlighted an agreement with the DOJ to settle the investigation for $29.75 million. This disclosure revealed that further financial repercussions could arise in the future, triggering another 9.88% drop in the stock price, finishing at $31.00 on April 16, 2025. This pattern of disclosure has raised eyebrows and alarmed shareholders, as the perceived lack of transparency in managing critical legal matters could signify a breach of investor trust.
For any shareholders of Semler Scientific, now is a crucial moment to become involved in this class action lawsuit. Those wishing to take on the role of lead plaintiff – which would provide the opportunity to represent the interests of the entire class – must file their paperwork by October 28, 2025. It is vital to understand that participating in this lawsuit does not require a financial commitment upfront; representation operates on a contingency basis, meaning shareholders will not incur any legal fees unless a recovery is achieved.
Robbins LLP, a reputable firm recognized for advocating shareholder rights, emphasizes their commitment to helping investors reclaim losses and ensure corporate governance accountability. Their team has been on the forefront of litigations aimed at protecting shareholder interests since the firm’s inception in 2002.
Moreover, all Semler Scientific stakeholders are encouraged to stay informed. One way to do so is by signing up for updates through services provided by Robbins LLP. This ensures investors are alerted to any settlements or new developments regarding misconduct by corporate executives. It’s important that investors are not left uninformed about potential remedies or legal recourse in such precarious financial waters.
If you or anyone you know has endured substantial financial losses due to investments in Semler Scientific, the team at Robbins LLP is available for assistance. Shareholders can reach out to attorney Aaron Dumas, Jr., or call the firm directly at (800) 350-6003 for further clarity and support.
In these challenging times, understanding your rights as a shareholder is vital. Engage, understand, and if necessary, act — your investments deserve the protection and advocacy only a dedicated legal team can provide.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.